Icatibant Acetate 相關新聞

← 返回新聞總覽


Icatibant Acetate 目前有 0 則相關新聞報導,預測適應症 20 個。

本頁整合 Icatibant Acetate 的 AI 預測適應症與最新健康新聞,橘色標示的適應症表示近期有相關新聞報導。
藥物資訊
  • 原適應症:Icatibant Accord is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children aged 2 years and older, with C1 esterase inhibitor...
  • 證據等級:L5
  • 預測適應症(20 個):
    • C1 inhibitor deficiency(100.0%)
    • hereditary angioedema with C1Inh deficiency(100.0%)
    • serpinopathy with toxic serpin polymerization(100.0%)
    • hereditary angioedema(99.4%)
    • pseudo-von Willebrand disease(99.2%)
    • primary release disorder of platelets(99.1%)
    • immune-mediated necrotizing myopathy(99.1%)
    • antisynthetase syndrome(99.0%)
    • Glanzmann thrombasthenia(99.0%)
    • focal myositis(99.0%)
    • Scott syndrome(98.8%)
    • inflammatory myopathy with abundant macrophages(98.8%)
    • idiopathic eosinophilic myositis(98.8%)
    • Peyronie disease(98.6%)
    • pancreatitis(98.0%)
    • pernicious anemia(97.9%)
    • thrombotic thrombocytopenic purpura(97.9%)
    • inherited thrombophilia(97.4%)
    • selective IgG immunodeficiency(97.3%)
    • bleeding diathesis due to a collagen receptor defect(97.3%)

查看完整藥物報告 →

相關新聞(0 則)

目前沒有相關新聞報導。當有新聞提到此藥物時,系統會自動收集並顯示在這裡。

免責聲明:本頁新聞由系統自動收集,僅供研究參考,不構成醫療建議。

Copyright © 2026 EuTxGNN Project. For research purposes only. Not medical advice.

This site uses Just the Docs, a documentation theme for Jekyll.